Algocell: ai-powered digital twin platform for fermentation optimization
Algocell offers an AI-driven digital twin platform for optimizing bioreactor-based manufacturing, enhancing yield, reducing energy use, and ensuring scalability. It integrates mechanistic knowledge with machine learning to improve operational efficiency and time-to-market.
Overview
Algocell presents an innovative AI-powered digital twin platform designed to revolutionize fermentation optimization in bioreactor-based manufacturing. By leveraging hybrid algorithms that integrate mechanistic biological knowledge with machine learning, Algocell's platform models complex biological systems even in data-sparse environments. This approach significantly enhances operational efficiency, achieving substantial improvements in yield and profitability while reducing the time-to-market.
Technical specifications
Key features:
- Yield Enhancement: Demonstrated a 2.5-fold increase in protein yield for E. coli and a 20% biomass increase in Pichia yeast during pilot trials.
- Energy Efficiency: Achieved a 25% reduction in production time, leading to decreased energy consumption.
- Soft Sensors: Provides inline monitoring with over 90% accuracy for methanol and over 95% for biomass, facilitating precise feed control and waste reduction without the need for new hardware.
- Scalability: Rapid deployment of hybrid models validated with partners within a 3-24 month window.
Technology readiness level
Currently, the technology is at TRL 6, with successful pilot validations and a structured 6-month delivery plan in place for further development. Algocell's platform has been calibrated and modeled through lab-scale experiments and is undergoing optimization and verification in partner facilities.
About Algocell.ai
Algocell is an AI-powered bioprocess modeling platform that combines traditional bioprocess engineering with machine learning to create Digital Twins. The platform enables users to upload biological and engineering data to calibrate highly accurate models, allowing for the simulation of thousands of in-silico scenarios. This approach is designed to replace costly, time-consuming trial-and-error experimentation with simulated insights, helping companies validate conceptual designs and predict outcomes during both development and manufacturing phases. By leveraging this hybrid modeling approach—which integrates biological mechanistic models with advanced AI—the platform provides a versatile infrastructure that adapts to specific cell line metabolism and equipment constraints.
This technology is primarily targeted at cell-based companies within industries such as foodtech, biotechnology, and pharmaceuticals, particularly those involved in precision fermentation and cultivated food production. By reducing trial-and-error experiments, Algocell helps these organizations accelerate their time-to-market and optimize cell productivity while ensuring consistent production quality. The company, headquartered in Rehovot, Israel, and founded in 2023, focuses on empowering biomanufacturing firms to maximize their process efficiency, increase margins, and achieve seamless transitions from pilot testing to full-scale production.
delivered to your inbox.